Medication info

Lozacom F Tablets (Losartan Potassium, Hydrochlorothiazide)

Prescription medicationApproval withdrawn
Ingredient · strength
Losartan Potassium›Strength being verifiedHydrochlorothiazide›Strength being verified
Manufacturer / importer
Hallym Pharmaceutical Co., Ltd.
Appearance
Light yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 200808460 · Notified 2008.08.06

This product's status changed to Approval withdrawn on 2023.07.14. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of losartan potassium 100 mg/hydrochlorothiazide 25 mg 1 tablet once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily, up to 1 tablet. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: The overall blood pressure-lowering effect can be maintained while reducing the hydrochlorothiazide dose by starting with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or greater. Use in patients with more severe renal impairment is not recommended, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use in patients with hepatic impairment requiring dose adjustment is not recommended, because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered with this medicine.
Children's dosage
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Hallym Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication, used in combination with Losartan Potassium and Hydrochlorothiazide, is designed to help patients with hypertension achieve proper blood pressure control. It is particularly effective in cases where adequate blood pressure is not achieved with a single agent. The two components complement each other to dilate blood vessels and regulate salt and fluid in the body, thereby helping to lower blood pressure. This medication plays a crucial role in managing blood pressure reliably, thus reducing the risk of cardiovascular diseases. Therefore, it is used in the treatment of hypertension.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken regardless of meals. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of losartan potassium 100 mg/hydrochlorothiazide 25 mg 1 tablet once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily, up to 1 tablet. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: The overall blood pressure-lowering effect can be maintained while reducing the hydrochlorothiazide dose by starting with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or greater. Use in patients with more severe renal impairment is not recommended, because loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use in patients with hepatic impairment requiring dose adjustment is not recommended, because the initial dose of losartan potassium for these patients, 25 mg, cannot be administered with this medicine.

Children's dosage

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to the components of this medication or with specific kidney or liver diseases should not take it. Patients with electrolyte imbalances such as hypokalemia or hypercalcemia should also exercise caution. Patients with excessively low blood pressure or decreased blood volume, those with renal artery stenosis, and the elderly or those with a history of diabetes or gout should take this medication with care. The Hydrochlorothiazide component can cause electrolyte imbalances, so regular blood tests should be conducted to monitor electrolyte status, and if symptoms occur, consultation with a physician should be sought immediately. Dizziness or drowsiness may occur while taking this medication, so caution is needed when driving or operating machinery. There may be interactions with other medications, so patients taking potassium supplements or medications containing potassium, non-steroidal anti-inflammatory drugs, or lithium preparations should inform their doctor. Possible adverse reactions include dizziness, cough, rash, muscle pain, indigestion, etc.; if severe side effects occur, immediate consultation with healthcare professionals is necessary. This medication has insufficient experience in children and adolescents, so it is advisable not to administer it to them. Lastly, this medication should be stored out of reach of children, kept in its original container, and should not be taken with grapefruit juice.

Side effects

  • Abdominal pain
  • swelling
  • palpitations
  • back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
Show 122 more
  • peau d'orange
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina pectoris
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • nerve hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbances
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reactions
  • itching
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • decreased vision
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • seizures
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • agitation
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • yellow vision
  • acute myopia
  • acute angle-closure glaucoma
  • dry cough
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a light-blocking, airtight container. Additionally, it is best stored at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Light yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.